（文章来源：证券日报） 证券日报网讯 1月6日，力合科创在互动平台回答投资者提问时表示，公司参股企业兰度生物经营正 常，其主营产品为高端生物医用材料，目前主要应用于创面、口腔、消化道、神经肌腱等领域。力合云 记的主营业务为自消杀抗病毒功能材料及相关解决方案。上述两家企业的业务与技术均未涉及脑机接口 概念，敬请注意投资风险。 ...

近日，上海昊海生物科技股份有限公司发布了关于公司实际控制人收到监管处罚的公告，引发了市场关 注。根据公告内容，公司控股股东、实际控制人之一蒋伟先生因其个人在证券市场的相关行为，收到了 中国证券监督管理委员会下发的《行政处罚决定书》。 监管部门的调查认定，蒋伟先生存在内幕交易及建议他人买卖证券的行为，并据此作出了相应的处罚决 定。此次事件所涉及的整个过程，自今年早些时候收到立案告知书至最终处罚决定下达，历时数月，现 已告一段落。 对于此次处罚，昊海生科在公告中迅速且明确地作出了回应。公司强调，该《行政处罚决定书》所针对 的主体是蒋伟先生个人，其涉及的事项属于个人行为范畴，与昊海生科上市公司本身的运营并无关联。 公司进一步说明，蒋伟先生并未参与公司的日常经营与管理工作，因此，预计该事项不会对昊海生科的 日常经营活动、业务开展以及财务状况构成重大影响。目前，公司各项生产经营活动均保持正常有序的 状态。 尽管公司明确将此次事件界定为实际控制人的个人行为，并与上市公司实体进行了切割，但其仍然促使 市场将目光投向上市公司的治理结构与未来发展。作为国内生物医用材料领域的知名企业，以及首家实 现"港股+科创板"两地上市的医药 ...

强化融合支撑,建强平台体系,贯通行业创新"协同链"。威海市工信局坚持围绕产业链部署创新链,推动创 新要素向产业链各环节精准配置,构建起全链条创新支撑体系。建强平台体系,"十四五"期间全市工业和 信息化领域建成省级及以上科技创新平台229家,实现10条标志性产业链"全覆盖"；新增省级制造业创新 中心3家,总数达6家,位列全省第3；工信部威海电子信息技术综合研究中心成功入选国家级产业技术基础 公共服务平台,实现国家级产业技术基础平台零的突破。推动成果转化,针对科技成果转化"最后一公 里"难题,支持园区和龙头企业共建中试平台,其中碳纤维及复合材料中试平台入选全省首批制造业中试平 台(全省仅9个),为前沿技术从实验室走向生产线提供了关键支撑,推动科技创新与产业创新互融共促。 凝聚聚合效能,营造创新生态,构建区域创新"共同体"。威海市工信局以"政产学研金服用"七位一体体系 为核心纽带,重点强化不同主体、不同区域间的创新联动,打破资源壁垒,让创新要素高效流动。深化产学 研协同,推动创新链条深度融合,建立与高等院校、科研院所的常态化对接机制,充分发挥行业协会、产业 联盟桥梁作用,以"企业出题、高校院所解题、政府搭台保障"模 ...

强化融合支撑，建强平台体系，贯通行业创新"协同链"。威海市工信局坚持围绕产业链部署创新链，推 动创新要素向产业链各环节精准配置，构建起全链条创新支撑体系。建强平台体系，"十四五"期间全市 工业和信息化领域建成省级及以上科技创新平台229家，实现10条标志性产业链"全覆盖"；新增省级制 造业创新中心3家，总数达6家，位列全省第3；工信部威海电子信息技术综合研究中心成功入选国家级 产业技术基础公共服务平台，实现国家级产业技术基础平台零的突破。推动成果转化，针对科技成果转 化"最后一公里"难题，支持园区和龙头企业共建中试平台，其中碳纤维及复合材料中试平台入选全省首 批制造业中试平台（全省仅9个），为前沿技术从实验室走向生产线提供了关键支撑，推动科技创新与 产业创新互融共促。 凝聚聚合效能，营造创新生态，构建区域创新"共同体"。威海市工信局以"政产学研金服用"七位一体体 系为核心纽带，重点强化不同主体、不同区域间的创新联动，打破资源壁垒，让创新要素高效流动。深 化产学研协同，推动创新链条深度融合，建立与高等院校、科研院所的常态化对接机制，充分发挥行业 协会、产业联盟桥梁作用，以"企业出题、高校院所解题、政府搭台保障" ...

位于苏州工业园区的博创生物，自2022年6月成立以来，瞄准胶原蛋白创新应用，一方面成功量产高纯 度、高活性的胶原蛋白，另一方面利用新技术将胶原蛋白研制成人工角膜基质片、口腔骨组织引导膜等 产品。短短3年半，该公司完成3轮融资，获评高新技术企业和"科创未来之星"企业。 好技术走出实验室 博创生物的核心技术，源自中国科学院院士刘昌胜领衔、华东理工大学材料科学与工程学院教授屈雪负 责的科研团队。屈雪也是博创生物创始人、首席技术官。她介绍，胶原蛋白是一种非常重要的蛋白质， 占人体所有蛋白质的25%-30%。由于具有良好的生物相容性、可生物降解性以及生物学活性，胶原蛋白 可以制成生物组织功能膜(即生物医用材料)，用于创伤修复、医疗美容等领域。团队多年深耕可控电化 学组装(EDP)技术，相关研究成果近年来发表在《Advanced Materials》《Advanced Science》等材料科 学领域的顶尖期刊。 EDP技术有多强？它通过电信号引导胶原蛋白分子定向迁移、组装，还能精准调控胶原蛋白分子组装成 的材料的微观结构。公司创始人、总经理谈浩琪博士解释，如果把生物组织功能膜比喻成胶原蛋白分子 组成的房子，利用传统技术 ...

Core Points - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with a total of 86 units selected across 35 categories [2] - Five companies from Shandong have been selected, including Weihai Weigao Blood Collection Consumables Co., Ltd., Qingdao Haier Biomedical Co., Ltd., Shandong Guyu Spring Biotechnology Co., Ltd., Shandong Weigao Group Medical Polymer Products Co., Ltd., and Shandong Guocer Functional Materials Co., Ltd. [2] - The selected companies are focusing on various innovative materials such as polyethylene terephthalate, non-phthalate plasticizers, polyester-polyethylene glycol copolymers, high-end polypropylene, and 3D printing zirconia ceramic ink [2] Industry Support - Local industrial and information authorities will collaborate with drug supervision departments to enhance tracking and support for the selected units and projects [2] - There will be prioritized allocation of resources such as project land, energy, and pollution discharge indicators for the selected units [2] - After completing the innovation tasks within three years, the Ministry of Industry and Information Technology and the National Medical Products Administration will commission professional institutions to evaluate and select the outstanding units, with a limit of two winners per product [2]

Core Insights - The 10th "Innovation and Entrepreneurship Competition" in the new materials sector concluded successfully, aiming to integrate innovation and industry for high-quality development in Jiangsu [1][8] - A total of 30 high-quality projects competed in two categories, showcasing advancements in high-performance metals, new energy materials, biomedical materials, and energy-saving polymers [3] Competition Highlights - The competition awarded 6 first prizes, 10 second prizes, and 13 third prizes, highlighting projects with leading technologies and clear business models [3] - The first prize in the innovation category was awarded to a project focused on a new green smelting process for high-carbon ferrochrome, addressing issues like complex production processes and high carbon emissions [3] - The first prize in the entrepreneurship category was given to a project developing laser-etched anti-counterfeiting flexible labels, combining polymer composites with nanomaterials for various high-security applications [3] Policy and Support - Jiangsu's provincial officials emphasized the importance of new materials as a foundation for manufacturing and technological innovation, urging researchers to focus on key technologies and deepen industry-academia collaboration [4] - The Peixian Economic Development Bureau introduced local industrial policies aimed at building a modern industrial system and attracting innovative talent [6] Future Directions - The competition has established itself as a vital platform for promoting innovation and the integration of technology and economy in Jiangsu, with plans to continue focusing on strategic emerging industries [8]

Group 1: Core Insights - The article discusses the financing status and trends in the biomedical materials industry in China from 2020 to 2025, highlighting significant investment events and the overall investment landscape [1][5][19]. Group 2: Financing Events Summary - A summary of major financing events in the biomedical materials industry from 2020 to 2025 is provided, detailing various companies, funding rounds, amounts, and investors [2][3][4]. - Notable financing events include: - Xintai Medical received 129.78 million RMB in strategic investment on June 23, 2025 [2]. - SupiraMedical raised 40 million USD in a D round on November 22, 2023 [3]. - Multiple companies, such as MoDi Bio and Rongmai Medical, have engaged in various funding rounds, indicating a vibrant investment environment [2][3][4]. Group 3: Financing Scale Analysis - The financing scale in the biomedical materials manufacturing industry shows a trend of "initial rise, peak, and subsequent adjustment," with financing occurrences peaking at 13 in 2021 and dropping to 4 in the first half of 2025 [5]. - The total financing amount reached a peak of 5.473 billion RMB in 2021, followed by a significant decline to 201 million RMB in the first half of 2025 [5]. Group 4: Financing Rounds Analysis - Since 2020, early-stage financing rounds have dominated, with A rounds being the most active at 15 occurrences, followed by angel rounds at 9 [7]. - Early-stage rounds (angel, Pre-A, A, and A+ rounds) accounted for over 60% of total financing events, indicating a preference for investing in early-stage companies [7]. Group 5: External Investment Landscape - The primary regions for external investments by major biomedical materials companies in China are Beijing and Shanghai, with 30 and 25 investments, respectively [10]. - The industry investment layout shows that scientific research and technical services account for 42%, manufacturing for 23%, and wholesale and retail for another 23% [11]. Group 6: Mergers and Acquisitions - The mergers and acquisitions market in the biomedical materials sector is characterized by continuous growth, with horizontal mergers being the primary focus, supported by policy incentives and industry demands [12]. - Recent notable transactions include: - SINOCERA's acquisition of DEKEMA for 10.21 million RMB, enhancing its product layout in the dental field [15]. - The acquisition of SPIDENT by SINOCERA for 704 million RMB, aimed at expanding its presence in the dental medical field [15]

Core Insights - The article discusses the evolution of policies supporting the development of the biomedical materials industry in China, highlighting a shift from basic research support to industrialization, innovation-driven growth, and high-quality development [1][3]. Policy Overview - Since 2015, multiple government departments, including the State Council and the National Health Commission, have issued various policies to support and regulate the biomedical materials industry, focusing on technology development, industry upgrades, quality standards, and centralized procurement [3][4]. - Key policies include the 2024 notification on centralized procurement of high-value medical consumables, aimed at enhancing procurement efficiency and reducing costs [4][5]. - The "14th Five-Year Plan" emphasizes the development of high-end medical devices and key technologies, aiming to improve supply capabilities and address gaps in high-end medical equipment [9][10]. Development Goals - The focus is on technological innovation in high-end implantable products, such as biodegradable vascular stents and artificial joints, as well as new materials like recombinant collagen and biodegradable materials [8][9]. - The government aims to optimize approval processes, promote bulk procurement, and enhance collaboration among academia, industry, and healthcare to boost competitiveness and domestic production levels [8][10]. - By 2025, the goal is to achieve comprehensive coverage of DRG/DIP payment methods in all eligible medical institutions, ensuring a more efficient healthcare financing system [10]. Regional Policies - Various provinces have introduced policies to promote the biomedical materials industry, with a focus on centralized procurement for orthopedic implants and other high-value medical consumables [12][13]. - Cities like Beijing and Shanghai are encouraging the development of new biomedical materials and technologies, including advanced manufacturing techniques and 3D bioprinting [13][14]. - The policies aim to strengthen the local manufacturing capabilities and foster innovation in the biomedical materials sector [14][17].

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the list of selected units for the second batch of the innovative task for biomedical materials, highlighting Jiangsu's leading position in this field with 20 projects selected, the highest in the country [1] Group 1: Project Overview - The biomedical materials innovation task aims to address critical technological challenges in the field and select the most capable innovators for focused breakthroughs in high-end medical materials [1] - Jiangsu's selected projects cover 14 categories of biomedical materials across three directions: inorganic non-metallic materials, polymer materials, and metal materials [1] Group 2: Application and Market Potential - These biomedical materials are widely used in high-value medical devices such as artificial joints, vascular stents, artificial bone repair, oral repair, and wound repair, indicating significant clinical application value and market promotion potential [1] - The increase in the number of applications and selections from Jiangsu compared to the previous round demonstrates substantial growth and potential for new growth points in the integration of new material clusters and biomedicine clusters [1] Group 3: Support and Development - Selected enterprises will receive policy support in financing, review, and registration after completing their tasks, which will accelerate the market launch process of biomedical materials and medical device products in Jiangsu [1]